Expenses
Net expenses totaled $3.1 million and $8.9 million, respectively, for the three and nine months ended September 30, 2020, of which $1.0 million and $3.3 million, respectively, were gross base management fees and gross performance-based incentive fees and $1.9 million and $6.1 million, respectively, were interest and other credit facility expenses. Over the same periods, $0.7 and $2.6 million, respectively, of base management fees were waived and $0.0 million and $0.1 million, respectively, of performance-based incentive fees were waived. Administrative services and other general and administrative expenses totaled $0.9 million and $2.3 million, respectively, for the three and nine months ended September 30, 2020. Net expenses totaled $4.7 million and $13.7 million, respectively, for the three and nine months ended September 30, 2019, of which $1.8 million and $5.2 million, respectively, were gross base management fees and gross performance-based incentive fees and $2.8 million and $8.2 million, respectively, were interest and other credit facility expenses. Over the same periods, $0.1 and $0.5 million, respectively, of base management fees were waived and $0.5 million and $1.6 million, respectively, of performance-based incentive fees were waived. Administrative services and other general and administrative expenses totaled $0.8 million and $2.4 million, respectively, for the three and nine months ended September 30, 2019. Expenses generally consist of management fees, performance-based incentive fees, administrative services expenses, insurance, legal expenses, directors’ expenses, audit and tax expenses, transfer agent fees and expenses, and other general and administrative expenses. Interest and other credit facility expenses generally consist of interest, unused fees, agency fees and loan origination fees, if any, among others. The decrease in net expenses year over year is primarily due to lower interest expense due to reductions in LIBOR and an increase in the waivers of fees.
Net Investment Income
The Company’s net investment income totaled $4.8 million and $15.6 million, or $0.30 and $0.97, per average share, respectively, for the three and nine months ended September 30, 2020. The Company’s net investment income totaled $5.7 million and $17.0 million, or $0.35 and $1.06, per average share, respectively, for the three and nine months ended September 30, 2019.
Net Realized Gain (Loss)
The Company had investment sales and prepayments totaling approximately $38.7 million and $115.7 million, respectively, for the three and nine months ended September 30, 2020. Net realized gains over the same periods were $0.04 million and $0.1 million, respectively. The Company had investment sales and prepayments totaling approximately $27.7 million and $55.1 million, respectively, for the three and nine months ended September 30, 2019. Net realized losses over the same periods were $5.0 million and $4.8 million, respectively. Net realized gains for the three and nine months ended September 30, 2020 were immaterial. Net realized losses for the three and nine months ended September 30, 2019 were primarily related to the Company’s exit of Trident USA Health Services partially offset by gains on the exit of Engineering Solutions & Products, LLC.
Net Change in Unrealized Gain (Loss)
For the three and nine months ended September 30, 2020, net change in unrealized gain (loss) on the Company’s assets and liabilities totaled $3.8 million and ($8.6) million, respectively. For the three and nine months ended September 30, 2019, net change in unrealized gain on the Company’s assets and liabilities totaled 4.5 million and $5.0 million, respectively. Net unrealized gain for the three months ended September 30, 2020 is primarily due to appreciation on our investments in Confie Seguros Holding II Co., Advantage Sales and Marketing, Inc., Unified Physician Management, LLC and US Radiology Specialists, Inc., among others, partially offset by the reversal of previously recognized unrealized appreciation in the value of our investment in Solara Medical Supplies, Inc. as well as depreciation in the value of our investment in TwentyEighty, Inc. Net unrealized loss for the nine months ended September 30, 2020 is primarily due to depreciation on our investments in North Mill Holdco LLC, Gemino Healthcare Finance, LLC, Composite Technology Acquisition Corp., DISA Holdings Acquisition Subsidiary Corp. and SHO Holdings I Corporation, among others, partially offset by appreciation on our investments in RxSense Holdings LLC and Advantage Sales and Marketing, Inc., among others. Net unrealized gain for the three months ended September 30, 2019 is primarily due to the reversal of previously recorded unrealized loss on Trident USA Health Services as well as appreciation on our investments in TwentyEighty, Inc. and Gemino Healthcare Finance, LLC, among others, partially offset by depreciation in NM Holdco and Confie Seguros Holding II Co., among others. Net unrealized gain for the nine months ended September 30, 2019 is primarily due to the reversal of previously recorded unrealized loss on Trident USA Health Services as well as appreciation on our investments in TwentyEighty, Inc. and Gemino Healthcare Finance, LLC, among others, partially offset by depreciation in NM Holdco, Aegis Toxicology Sciences Corporation and American Teleconferencing Services, Ltd., among others. The year over year net change in unrealized loss for the nine month period ended September 30, 2020 is impacted by uncertainty due to the COVID-19 pandemic and its effect on market yields and fundamental portfolio company performance.
36